Raw data outputs 1-18

Raw data outputs 1-18
Raw data output 1. Differentially expressed genes in AML CSCs compared with GTCs as well as in TCGA AML cancer samples compared with normal ones. This data was generated based on the results of AML microarray and TCGA data analysis.
Raw data output 2. Commonly and uniquely differentially expressed genes in AML CSC/GTC microarray and TCGA bulk RNA-seq datasets. This data was generated based on the results of AML microarray and TCGA data analysis.
Raw data output 3. Common differentially expressed genes between training and test set samples the microarray dataset. This data was generated based on the results of AML microarray data analysis.
Raw data output 4. Detailed information on the samples of the breast cancer microarray dataset (GSE52327) used in this study.
Raw data output 5. Differentially expressed genes in breast CSCs compared with GTCs as well as in TCGA BRCA cancer samples compared with normal ones.
Raw data output 6. Commonly and uniquely differentially expressed genes in breast cancer CSC/GTC microarray and TCGA BRCA bulk RNA-seq datasets. This data was generated based on the results of breast cancer microarray and TCGA BRCA data analysis. CSC, and GTC are abbreviations of cancer stem cell, and general tumor cell, respectively.
Raw data output 7. Differential and common co-expression and protein-protein interaction of genes between CSC and GTC samples. This data was generated based on the results of AML microarray and STRING database-based protein-protein interaction data analysis. CSC, and GTC are abbreviations of cancer stem cell, and general tumor cell, respectively.
Raw data output 8. Differentially expressed genes between AML dormant and active CSCs. This data was generated based on the results of AML scRNA-seq data analysis.
Raw data output 9. Uniquely expressed genes in dormant or active AML CSCs. This data was generated based on the results of AML scRNA-seq data analysis.
Raw data output 10. Intersections between the targeting transcription factors of AML key CSC genes and differentially expressed genes between AML CSCs vs GTCs and between dormant and active AML CSCs or the uniquely expressed genes in either class of CSCs.
Raw data output 11. Targeting desirableness score of AML key CSC genes and their targeting transcription factors. These scores were generated based on an in-house scoring function described in the Methods section.
Raw data output 12. CSC-specific targeting desirableness score of AML key CSC genes and their targeting transcription factors. These scores were generated based on an in-house scoring function described in the Methods section.
Raw data output 13. The protein-protein interactions between AML key CSC genes with themselves and their targeting transcription factors. This data was generated based on the results of AML microarray and STRING database-based protein-protein interaction data analysis.
Raw data output 14. The previously confirmed associations of genes having the highest targeting desirableness and CSC-specific targeting desirableness scores with AML or other cancers’ (stem) cells as well as hematopoietic stem cells. These data were generated based on a PubMed database-based literature mining.
Raw data output 15. Drug score of available drugs and bioactive small molecules targeting AML key CSC genes and/or their targeting transcription factors. These scores were generated based on an in-house scoring function described in the Methods section.
Raw data output 16. CSC-specific drug score of available drugs and bioactive small molecules targeting AML key CSC genes and/or their targeting transcription factors. These scores were generated based on an in-house scoring function described in the Methods section.
Raw data output 17. Candidate drugs for experimental validation. These drugs were selected based on their respective (CSC-specific) drug scores. CSC is the abbreviation of cancer stem cell.
Raw data output 18. Detailed information on the samples of the AML microarray dataset GSE30375 used in this study.

原始数据输出1至18
原始数据输出1：急性髓系白血病（Acute Myeloid Leukemia，AML）癌症干细胞（cancer stem cell，简称CSC）与普通肿瘤细胞（general tumor cell，简称GTC）的差异表达基因，以及癌症基因组图谱（The Cancer Genome Atlas，简称TCGA）中AML癌样本与正常样本的差异表达基因。该数据基于AML芯片及TCGA数据分析结果生成。
原始数据输出2：AML癌症干细胞/普通肿瘤细胞芯片与TCGA批量RNA测序（bulk RNA-seq）数据集中共有的及特有的差异表达基因。该数据基于AML芯片及TCGA数据分析结果生成。
原始数据输出3：芯片数据集中训练集与测试集样本共有的差异表达基因。该数据基于AML芯片数据分析结果生成。
原始数据输出4：本研究使用的乳腺癌芯片数据集（GSE52327）的样本详细信息。
原始数据输出5：乳腺癌癌症干细胞与普通肿瘤细胞的差异表达基因，以及TCGA中乳腺癌（Breast Cancer，简称BRCA）癌样本与正常样本的差异表达基因。
原始数据输出6：乳腺癌癌症干细胞/普通肿瘤细胞芯片与TCGA BRCA批量RNA测序数据集中共有的及特有的差异表达基因。该数据基于乳腺癌芯片及TCGA BRCA数据分析结果生成。其中，CSC与GTC分别为癌症干细胞与普通肿瘤细胞的缩写。
原始数据输出7：癌症干细胞与普通肿瘤细胞样本间基因的差异表达、共表达及蛋白-蛋白互作的共有特征。该数据基于AML芯片及STRING数据库（STRING database）的蛋白-蛋白互作数据分析结果生成。其中，CSC与GTC分别为癌症干细胞与普通肿瘤细胞的缩写。
原始数据输出8：AML休眠与活化态癌症干细胞间的差异表达基因。该数据基于AML单细胞RNA测序（scRNA-seq）数据分析结果生成。
原始数据输出9：休眠或活化态AML癌症干细胞中特异性表达的基因。该数据基于AML单细胞RNA测序数据分析结果生成。
原始数据输出10：AML关键癌症干细胞基因的靶向转录因子，与AML癌症干细胞vs普通肿瘤细胞、休眠与活化态AML癌症干细胞间的差异表达基因，或任一类别癌症干细胞中特异性表达基因的交集集合。
原始数据输出11：AML关键癌症干细胞基因及其靶向转录因子的靶向适宜性评分。此类评分基于方法部分描述的自研评分函数生成。
原始数据输出12：AML关键癌症干细胞基因及其靶向转录因子的癌症干细胞特异性靶向适宜性评分。此类评分基于方法部分描述的自研评分函数生成。
原始数据输出13：AML关键癌症干细胞基因自身及其靶向转录因子间的蛋白-蛋白互作关系。该数据基于AML芯片及STRING数据库的蛋白-蛋白互作数据分析结果生成。
原始数据输出14：靶向适宜性评分及癌症干细胞特异性靶向适宜性评分最高的基因，与AML或其他癌症（干）细胞及造血干细胞的已证实关联。此类数据基于PubMed数据库的文献挖掘结果生成。
原始数据输出15：针对AML关键癌症干细胞基因及/或其靶向转录因子的现有药物及生物活性小分子的药物评分。此类评分基于方法部分描述的自研评分函数生成。
原始数据输出16：针对AML关键癌症干细胞基因及/或其靶向转录因子的现有药物及生物活性小分子的癌症干细胞特异性药物评分。此类评分基于方法部分描述的自研评分函数生成。
原始数据输出17：用于实验验证的候选药物。此类药物基于其对应的（癌症干细胞特异性）药物评分筛选得到。其中，CSC为癌症干细胞的缩写。
原始数据输出18：本研究使用的AML芯片数据集GSE30375的样本详细信息。